Clovis Oncology Inc. (NASDAQ:CLVS) shares fell 17.8 percent on Friday as investors wrestled with the competitive implications of data submitted in rucaparib's new drug application (NDA) and presented at the European Society for Medical Oncology congress in Copenhagen. p>